Neutra NTRR

Neutra Corp. engages in the nutraceutical industry, concentrating on the development and marketing of products derived from natural and organic sources, with a specific focus on hemp‑derived cannabinoids such as delta‑8‑THC and CBD. The company aims to introduce innovative technology to the nutraceutical sector and intends to private‑label its formulations through third‑party contractors, allowing it to sell under its own brand without owning manufacturing facilities. Neutra Corp. has entered into an agreement with Artillery Labs to market and sell its natural nutraceutical products online, with the goal of establishing a dedicated line of legal CBD products distributed through Artillery Labs’ e‑commerce platform. In August 2019, the company acquired all outstanding shares of Vivis Corporation, a Wyoming‑based entity, from its chief executive officer for an upfront cash payment of $35,000 and a royalty arrangement that pays 40% of Vivis’s gross revenue until $100,000 is satisfied, then 25% until an additional $100,000 is paid, and thereafter a 10% royalty in perpetuity. To date, Neutra Corp. has generated only limited revenue, as its primary activities have consisted of business plan formulation, product research and development, and securing partnership agreements, and it acknowledges that additional financing will be required to fully commercialize its product suite and execute its long‑term strategy.

Revenue is generated chiefly through the sale of CBD, delta‑8‑THC, and related cannabinoid‑based products via the online sales infrastructure provided by Artillery Labs, under which Neutra Corp. supplies the product line and Artillery Labs handles the storefront, order processing, and fulfillment. The Artillery Labs partnership includes a milestone payment of $25,000 upon the successful launch of a product, which contributes to early‑stage cash inflow. Beyond the online channel, the company anticipates future revenue from the royalty stream associated with the Vivis acquisition, which entitles Neutra Corp. to a tiered percentage of Vivis’s gross sales as described above. Additional potential income streams include the sale of privately labeled nutraceutical products once sufficient capital is raised to scale production and expand the product catalog. The company has stated that its current cash reserves are insufficient to fund large‑scale manufacturing or extensive marketing campaigns, and that it will need to secure further financing to move beyond the developmental stage.

Neutra Corp. operates within a competitive and fast‑growing segment of the nutraceutical market that encompasses hemp‑derived cannabinoids, CBD oils, edibles, topicals, and wellness supplements. Numerous established firms and emerging entrants offer comparable products, creating a crowded marketplace where differentiation often hinges on branding, formulation innovation, and regulatory compliance. The company’s competitive advantages are rooted in its emphasis on technology‑driven product development, its private‑label manufacturing approach that limits fixed asset expenditures, and its reliance on an established online distribution partner that provides immediate market access. However, Neutra Corp. faces substantial headwinds from a complex and evolving regulatory landscape, including oversight by the FDA, DEA, FTC, and various state and local authorities, which can impose restrictions on the sale of delta‑8‑THC and other cannabinoids, create licensing requirements, or lead to enforcement actions that could materially affect its operations and share price.

The company’s customer base consists mainly of retail consumers who purchase hemp‑derived nutraceutical products through online channels, with the Artillery Labs platform serving as the primary storefront for its CBD and delta‑8‑THC offerings. While the filing does not disclose the names of individual buyers or specific retail partners, the target audience includes individuals seeking wellness supplements, alternative medicine products, and recreational cannabinoid‑based items. Neutra Corp. also indicates that its products may be appealing to consumers interested in natural and organic alternatives, and it anticipates demand from both domestic and, where permissible, international markets that allow the sale of hemp‑derived compounds.